Official Title Variation in Thoracic and Abdominal Shapes and their Influence on Posture and Seat Belt Fit for Adolescent Females

Purpose

We aim to understand how torso shape and bra design influence good vs. poor seat belt fit, posture, and comfort in cars.

Could this study be right for you?

To participate, you must be female, between 10–21 years old, in good health, a current bra-wearer, and willing to attend one 3-hour appointment at the OSU campus in Graves Hall (333 W. 10th Ave, Columbus, OH, 43210).

Age Range

10 - 21 years

Official Title Digital Transformation of CRC Screening: Revolutionizing Access and Saving Lives

Purpose

The purpose of this study is to conduct usability testing to evaluate ease of use and overall user experience of a website designed to promote colorectal (CRC) awareness and screening uptake among adults 45-64.

Could this study be right for you?

Inclusion Criteria: Eligible participants will 1) be between the ages of 45-64, 2) at average risk for CRC and 3) from diverse racial/ethnic and socioeconomic backgrounds 

 

Those who are ineligible fall under the following categories:  

1. Age: Individuals outside the age range of 45-64 will be excluded

2. Pregnancy Status: Pregnant individuals will be excluded from the study. since CRC screening is not recommended for pregnant individuals

Age Range

45 - 64 years

Official Title LOWFLC Study: Addiction potential of low nicotine filtered little cigars

Purpose

Researchers from The Ohio State University are recruiting adult users of little cigars and cigarillos to help improve understanding of the products’ health impact.

Could this study be right for you?

• Current smoker
• No significant health problems

Age Range

21 - 75 years

Official Title Brief Digitally Enhanced Intervention for Managing Emotional Pain and Reducing Alcohol Use during Medication for OUD (Phase Two)

Purpose

This study is being done to further examine and improve how a brief clinical treatment intervention may reduce alcohol use among patients engaged in medication for opioid use disorder (MOUD) treatment.

The length of the study is approximately 10 weeks and will include two on-campus lab visits at Ohio State's Medical Campus, daily surveys via a smartphone app (surveys 3 times a day for ~21 days), three treatment sessions (completed online or in-person), and follow-up questionnaires (completed online). The total time commitment of the study is 11 hours and 6 minutes.

Could this study be right for you?

Inclusion Criteria:

• engaged in MOUD treatment (for at least one month)
• alcohol consumption (within the past 12 months)
• age 18 or older
• access to a smart phone

(partial list of inclusion criteria)

Exclusion Criteria:

• diagnosis of psychosis or bipolar I
• currently pregnant (positive pregnancy test)

(partial list of exclusion criteria)

Age Range

18 years and up

Official Title Brief Digitally Enhanced Intervention for Managing Emotional Pain and Reducing Alcohol Use during Medication for OUD (Phase One)

Purpose

This study is being done to adapt and improve a brief clinical treatment intervention that aims to reduce alcohol use among patients engaged in medication for opioid use disorder (MOUD) treatment.

The length of the study is approximately 4 weeks and will include an initial study visit, daily surveys via a smartphone app (surveys 5 times a day for ~21 days), and three treatment sessions. All study sessions can be completed online or in-person. The total time commitment of the study is 8 hours and 30 minutes.

Could this study be right for you?

Inclusion Criteria:

• engaged in MOUD treatment (for at least one month)
• alcohol consumption (within the past 12 months)
• age 18 or older
• access to a smart phone

(partial list of inclusion criteria)

Age Range

18 years and up

Official Title Depressive Episodes Associated with Bipolar I or II Disorder: A Double-Blind,
Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of
ABBV-932

Purpose

The purpose of this study is to see if the investigational study drug is safe and useful for treating patients with bipolar depression.

Eligible participants will be randomized to receive the drug or placebo. A placebo looks just like the investigational study drug but has no active drug in it.

The maximum duration of the study treatment period is 6 weeks. Participants receive psychiatric evaluation at each visit, and physical exam, urine test and blood draws at some of the visits. All study medication and procedures are provided at no cost, and participants may be compensated for their time and travel for each visit attended.

Could this study be right for you?

A diagnosis of bipolar disorder (type I or II) and be currently depressed.

Age Range

18 - 65 years

Official Title A Multicenter, Randomized, Double-Blind, Parallel-Group
Dose-Controlled Study Evaluating the Safety and Efficacy of
RE104 for Injection in the Treatment of Patients with
Postpartum Depression (PPD)

Purpose

The purpose of this study is to compare the effectiveness of two doses of an experimental medication, administered once, in reducing symptoms of depression in patients with postpartum depression.

 

Eligible participants will be assigned by chance to one of the two doses of the medication. The study includes 6 in-person visits and 4 telephone calls for up to 8 weeks.

Could this study be right for you?

To be eligible for this study, participants must meet the following criteria:

• Female aged 18 to 45 years
• Less than 12 months since delivery
• Currently depressed
• Not currently breastfeeding

Age Range

18 - 45 years

Official Title A Phase III, multicentre, randomised, double-blind,
controlled study to investigate the efficacy, safety,
and tolerability of two initial administrations of
COMP360 in participants with treatment-resistant
depression

Purpose

The study investigates a new approach for treatment-resistant depression using an investigational medicine related to psilocybin alongside psychological support.

Could this study be right for you?

You may be able to join the study if you:

—         Are 18 years of age or older

—         Have been diagnosed with major depression and have not responded to 2+ antidepressants

Other criteria will need to be met to confirm your eligibility for this study, which will last up to 62 weeks.

Age Range

18 years and up

Official Title A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the
Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of
Patients with Major Depressive Disorder

Purpose

Depression is one of the most common mental health issues worldwide. Many people with major depressive disorder (MDD) take antidepressant medications that do not provide enough of a response to ease their depressive symptoms.

The primary objective of this study is to evaluate the benefit of Lumateperone 42 mg administered once daily compared with placebo as adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) who have an inadequate response to ongoing ADT.

Could this study be right for you?

You may be able to take part if you:

• are 18–65 years of age

• have a confirmed diagnosis of Major Depressive Disorder (MDD)

• feel that your current antidepressant medication is not working well

• Has tried 2 or more antidepressant medication in the current episode of depression

 

Other criteria will need to be met to confirm your eligibility for this study.

Age Range

18 - 65 years

Official Title Evaluation of Wear Experience with PRECISION7® For Astigmatism Contact Lenses in Neophyte Lens Wearers

Purpose

The purpose of this study is to explore the wear experience with PRECISION7® For Astigmatism lenses in adults who have not previously worn contact lenses.

Could this study be right for you?

1. Adults who have never worn contact lenses.
2. Adults who have astigmatism
3. Ability to attend 3 visits over the course of 3 weeks.
4. Satisfy all other study eligibility and exclusion criteria.

Age Range

18 - 40 years

Official Title The KOBRA Study: The Effects of Knee Osteoarthritis on Brain Activation

Purpose

The purpose of this study is to assess changes in brain activation and processing in those with right knee osteoarthritis compared to healthy controls. 

Could this study be right for you?

• Either two healthy knees OR those with right knee pain from a diagnosis of right knee osteoarthritis with a healthy left knee
• No metal implants that prevent you from having an MRI
• No foot/ankle/leg/hip surgeries in the past year
• No neurologic conditions
• No conditions that prevent athletic participation or maximal effort exercise
• Able to provide informed consent
• Speak and read English

Age Range

45 - 70 years

Official Title Establishing Reference Values and Clinical Decision Points for Quantitative Videofluoroscopic Measures of Swallowing

Purpose

This study will help create healthy reference values clinicians can use to evaluate adult patients of all ages and is sponsored by the National Institute on Aging.  During this study, we will perform an x-ray swallowing exam and breathing tests with persons who do not have a personal history of swallowing problems or any disorders that could contribute to a swallowing problem.  Study participation will consist of a screening meeting (approximately 15 minutes) via phone call, video chat, or email to verify eligibility, and one in-person visit to our laboratory (approximately 1 hour).

Could this study be right for you?

• If you are biologically female and of child-bearing age (<63), you must not be pregnant or breastfeeding.
• No personal history of surgery or radiation therapy to the head or neck (mouth, jaw, neck, brain, nose, face, thyroid, throat, or voice box) other than having your tonsils, adenoids, or teeth removed.
• No personal history of cancer involving structures of the head, neck, spine, respiratory, or lymphatic system.
• No personal history of stroke or other progressive nerve disease.
• No current diagnosis or personal history of Chronic Obstructive Pulmonary Disease (COPD).
• No known allergies to barium.

Age Range

54 - 89 years